With the presidential transition in full swing and Congress back in session, there's lots to cover in this week's advocacy update!

This week's update includes information on pharmacy champions getting leadership roles in Congress, a delay in Part D prescriber enrollment, and an updated "do not compound" list from the FDA.

This week's Advocacy Center update includes information on support for federal legislation opposing retroactive DIR fees, a request for a hearing into PBM practices, and more!

While Congress is back home until November 14th, what better time than to make a CONTACT regarding H.R. 5951 and S. 3308, “Improving Transparence and Accuracy in Medicare Part D Spending Act”?

In this week's roundup, learn about growing support for federal DIR legislation, Congressional hearings exposing PBM tactics, and more!